EUVIMEDEUVIMED entdecken
Crossref

Nanoparticle Albumin-Bound Bortezomib: Enhanced Antitumor Efficacy and Tumor Accumulation in Breast Cancer Therapy

Anita Saremi Poor, Bagher Davaeil, Marziyeh Ramezanpour, Mehdi Shafiee Ardestani, Ali Akbar Moosavi-Movahedi iD, S Mohsen Asghari iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Anita Saremi Poor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Biophysics (IBB), University of Tehran, 1417614411 Tehran, Iran. Hauptthemen laut MEDLINE: Nanoparticles, Bortezomib, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Institute for Medical Research Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanoparticle albumin-bound (NAB) formulations are emerging as a viable strategy for the intravenous delivery of poorly water-soluble drugs. This study aims to improve the therapeutic profile of Bortezomib (BTZ), addressing its low solubility and significant systemic toxicity through the development of NAB-BTZ nanoparticles. The synthesized nanoparticles exhibited an average size of 296.47 ± 10 nm and a high drug encapsulation efficiency of 75%, and a drug loading of 10%. NAB-BTZ displayed a controlled, pH-sensitive release profile, with 59% release at pH 5.4 (mimicking tumor environments) and 46% at pH 7.4 after 12 h. In vitro assays demonstrated that NAB-BTZ significantly reduced the viability of 4T1 mammary carcinoma cells in a dose- and time-dependent manner, increasing late apoptosis from 6% to 54% after 48 h, compared to 24% for free BTZ. At molecular level, NAB-BTZ induced apoptosis by upregulating p53 and Bax, downregulating Bcl-2, and activating caspases 3 and 7. In vivo tests in a murine 4T1 breast cancer model showed that NAB-BTZ substantially inhibited tumor growth, achieving an average tumor volume of 916 mm3 by day 31 versus 1400 mm3 for free BTZ, leading to an improved survival rate of 100% compared to 83% in the BTZ group. Technetium-99m (99mTc) labeling and SPECT imaging confirmed enhanced targeting capability, showing preferential accumulation of NAB-BTZ in tumor sites compared to free BTZ. These findings suggest that NAB-BTZ not only improves antitumor efficacy but also enhances its safety profile, underscoring its clinical potential in breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesBortezomibBreast NeoplasmsAntineoplastic AgentsAlbuminsAnimalsFemaleMiceCell Line, TumorApoptosisMice, Inbred BALB CHumans

Stichwörter der Autor:innen

NAB technologyalbuminbortezomibbreast cancertumor growth

Substanzen

BortezomibAntineoplastic AgentsAlbumins

Autor:innen und Institutionen

  • Institute of Biochemistry and Biophysics (IBB), University of Tehran, 1417614411 Tehran, Iran.
  • Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 1461884513 Tehran, Iran.
  • Research Center for Molecular Medicine, Shariati Hospital, North Kargar Avenue, 1411713135 Tehran, Iran.

ORCID-Profile: Ali Akbar Moosavi-Movahedi, S Mohsen Asghari

Förderung

  • National Institute for Medical Research Development

Zitieren

APA

Saremi Poor, A., Davaeil, B., Ramezanpour, M., Shafiee Ardestani, M., Moosavi-Movahedi, A. A., & Asghari, S. M. (2025). Nanoparticle Albumin-Bound Bortezomib: Enhanced Antitumor Efficacy and Tumor Accumulation in Breast Cancer Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01283

Vancouver

Saremi Poor A, Davaeil B, Ramezanpour M, Shafiee Ardestani M, Moosavi-Movahedi AA, Asghari SM. Nanoparticle Albumin-Bound Bortezomib: Enhanced Antitumor Efficacy and Tumor Accumulation in Breast Cancer Therapy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01283

BibTeX
@article{SaremiPoor2025,
  author = {Saremi Poor, Anita and Davaeil, Bagher and Ramezanpour, Marziyeh and Shafiee Ardestani, Mehdi and Moosavi-Movahedi, Ali Akbar and Asghari, S Mohsen},
  title = {Nanoparticle Albumin-Bound Bortezomib: Enhanced Antitumor Efficacy and Tumor Accumulation in Breast Cancer Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01283}
}
Kostenlos starten →